| Marcus Caide Harding, PHARMD | |
|
200 W Hospital Dr, Whiteriver, AZ 85941 | |
| (928) 338-3516 | |
| Not Available |
| Full Name | Marcus Caide Harding |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 200 W Hospital Dr, Whiteriver, Arizona |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194339747 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | S023992 (Arizona) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Marcus Caide Harding, PHARMD 4495 Stone Pine Dr, Pinetop, AZ 85935-8181 Ph: (520) 979-8693 | Marcus Caide Harding, PHARMD 200 W Hospital Dr, Whiteriver, AZ 85941 Ph: (928) 338-3516 |
News Archive
A team of investigators supported by the National Institute on Drug Abuse (NIDA), National Institutes of Health, has created a strain of mice scientists can use to study nicotine addiction and its associated behaviors.
NormOxys Inc., a biotechnology company developing a novel class of small molecule drugs which enhance the body's ability to deliver oxygen to diseased tissues, today announced that it has initiated a Phase 1 clinical trial of OXY111A, a novel allosteric modulator of affinity of oxygen to hemoglobin. NormOxys plans to initially develop this compound as a treatment for chronic heart failure and cancer indications.
Researchers from Massachusetts General Hospital for Children in Boston have determined that pediatric epilepsy significantly impacts sleep patterns for the child and parents. According to the study available in Epilepsia, a journal published by Wiley-Blackwell on behalf of the International League Against Epilepsy (ILAE), sharing a room or co-sleeping with their child with epilepsy decreases the sleep quality and prevents restful sleep for parents.
ImmunoCellular Therapeutics announced today that the U.S. Food and Drug Administration has granted orphan drug designation for ICT-107, the company's dendritic cell-based cancer vaccine candidate which targets glioblastoma multiforme. As a result of the orphan drug status, ImmunoCellular will be eligible to receive a number of benefits, including access to grant funding for clinical trials, tax credits, accelerated FDA approval and allowance for marketing exclusivity after drug approval for a period of up to seven years.
United Security Bancshares, Inc. today reported a net loss attributable to USBI of $348,000, or $0.06 per diluted share, for the second quarter ended June 30, 2010, compared with net income of $2.9 million, or $0.48 per diluted share, for the same period of 2009.
› Verified 5 days ago
Zebedee Walpert, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 200 West Hospital Drive, Whiteriver, AZ 85941 Phone: 928-338-4911 | |
Dr. Matthew Thomas Washburn, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 200 W Hospital Dr, Whiteriver Indian Hospital, Whiteriver, AZ 85941 Phone: 928-338-3501 Fax: 928-338-3510 | |
Dr. Jared Lee Hochstettler, PHARMD. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 200 W Hospital Dr., Whiteriver, AZ 85941 Phone: 928-338-4911 | |
Lia M Jasperse, PHARMD. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 200 West Hospital Drive, Whiteriver, AZ 85941 Phone: 928-338-3502 Fax: 928-338-3510 | |
Dr. Endrit Toska, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 200 W Hospital Dr, Whiteriver, AZ 85941 Phone: 928-338-3502 | |
Larissa Worster, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 200 W Hospital Dr, Whiteriver, AZ 85941 Phone: 928-338-4911 | |
Daniel J Mccarville, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 200 W Hospital Dr, Whiteriver, AZ 85941 Phone: 928-338-5500 |